Interleukin-8 as a modulator of response to bevacizumab in preclinical models of head and neck squamous cell carcinoma

Oral Oncology

Volumn 49, Issue 8, 2013, Pages 761-770

  Gyanchandani, Rekha ^a   Sano, Daisuke ^b,c   Ortega Alves, Marcus V ^b   Klein, Jonah D ^a   Knapick, Beth A ^a   Oh, Sanders ^a   Myers, Jeffrey N ^b   Kim, Seungwon ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF TEXAS   (United States)

^c YOKOHAMA CITY UNIVERSITY   (Japan)

Author keywords

Angiogenesis; Bevacizumab; Biomarker; HNSCC; IL 8 Resistance

Indexed keywords

BEVACIZUMAB; FIBROBLAST GROWTH FACTOR; INTERLEUKIN 1ALPHA; INTERLEUKIN 8; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER CHEMOTHERAPY; CANCER PATIENT; CONTROLLED STUDY; DRUG EFFICACY; DRUG RESPONSE; ENDOTHELIUM CELL; FEMALE; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; INTRACELLULAR SIGNALING; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR XENOGRAFT;

ANGIOGENESIS; BEVACIZUMAB; BIOMARKER; EGFR; EPIDERMAL GROWTH FACTOR RECEPTOR; FGF-A; FIBROBLAST GROWTH FACTOR-A; GCSF; GRANULOCYTE COLONY STIMULATING FACTOR; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HNSCC; IL-1Α; IL-8; INSTITUTIONAL ANIMAL CARE AND USE COMMITTEE; INTERLEUKIN-1Α; INTERLEUKIN-8; IUCUC; MICROVESSEL DENSITY; MVD; RCC; RENAL CELL CARCINOMA; RESISTANCE; TERMINAL DEOXYNUCLEOTIDYL TRANSFERASE-MEDIATED DUTP NICK END LABELING; TNF-Α; TUMOR NECROSIS FACTOR-Α; TUNEL; UNIVERSITY OF PITTSBURGH CANCER INSTITUTE; UPCI; VASCULAR ENDOTHELIAL GROWTH FACTOR; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR; VEGF; VEGFR;

ANIMALS; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; BASE SEQUENCE; CARCINOMA, SQUAMOUS CELL; DNA PRIMERS; DOWN-REGULATION; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; INTERLEUKIN-8; MICE; MICE, NUDE; NEOVASCULARIZATION, PATHOLOGIC; UP-REGULATION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84880058226     PISSN: 13688375     EISSN: 18790593     Source Type: Journal    
DOI: 10.1016/j.oraloncology.2013.03.452     Document Type: Article

References (42)

1. N. Ferrara, K.J. Hillan, H.P. Gerber, and W. Novotny Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer Nat Rev Drug Discov. 3 5 2004 391 400
2. S. Cao, F.A. Durrani, K. Toth, Y.M. Rustum, and M. Seshadri Bevacizumab enhances the therapeutic efficacy of Irinotecan against human head and neck squamous cell carcinoma xenografts Oral Oncol 47 6 2011 459 466
3. A. Bozec, A. Sudaka, J.L. Fischel, M.C. Brunstein, M.C. Etienne-Grimaldi, and G. Milano Combined effects of bevacizumab with erlotinib and irradiation: a preclinical study on a head and neck cancer orthotopic model Br J Cancer 99 1 2008 93 99
4. C.N. Prichard, S. Kim, and Y.D. Yazici Concurrent cetuximab and bevacizumab therapy in a murine orthotopic model of anaplastic thyroid carcinoma The Laryngoscope 117 4 2007 674 679
5. A. Argiris, A.P. Kotsakis, and T. Hoang Cetuximab and bevacizumab: preclinical data and phase II trial in recurrent or metastatic squamous cell carcinoma of the head and neck Ann Oncol 24 1 2012 220 225
6. J.D. Hainsworth, D.R. Spigel, and F.A. Greco Combined modality treatment with chemotherapy, radiation therapy, bevacizumab, and erlotinib in patients with locally advanced squamous carcinoma of the head and neck: a phase II trial of the Sarah Cannon oncology research consortium Cancer J 17 5 2011 267 272 210.1097/PPO.1090b1013e3182329791
7. E.E.W. Cohen, D.W. Davis, and T.G. Karrison Erlotinib and bevacizumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck: a phase I/II study Lancet Oncol 10 3 2009 247 257
8. M.V. Karamouzis, D. Friedland, R. Johnson, K. Rajasenan, B. Branstetter, and A. Argiris Phase II trial of pemetrexed (P) and bevacizumab (B) in patients (pts) with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC): an interim analysis J Clin Oncol (Meeting Abstracts). 25 18-suppl 2007 6049 June 20, 2007
9. E.E. Vokes, E.E.W. Cohen, and A.M. Mauer A phase I study of erlotinib and bevacizumab for recurrent or metastatic squamous cell carcinoma of the head and neck (HNC) J Clin Oncol (Meeting Abstracts) 23 16-suppl 2005 5504 June 1, 2005
10. G. Bergers, and D. Hanahan Modes of resistance to anti-angiogenic therapy Nat Rev Cancer. 8 8 2008 592 603
11. L.M. Ellis, and D.J. Hicklin Pathways mediating resistance to vascular endothelial growth factor-targeted therapy Clin Cancer Res 14 20 2008 6371 6375
12. Y. Crawford, and N. Ferrara Tumor and stromal pathways mediating refractoriness/resistance to anti-angiogenic therapies Trends Pharmacol Sci 30 12 2009 624 630
13. H.P. Eikesdal, and R. Kalluri Drug resistance associated with antiangiogenesis therapy Seminars Cancer Biol 19 5 2009 310 317
14. P. Carmeliet, and R.K. Jain Molecular mechanisms and clinical applications of angiogenesis Nature 473 7347 2011 298 307
15. O. Casanovas, D.J. Hicklin, G. Bergers, and D. Hanahan Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors Cancer Cell 8 4 2005 299 309
16. F. Shojaei, X. Wu, and A.K. Malik Tumor refractoriness to anti-VEGF treatment is mediated by CD11b+Gr1+ myeloid cells Nat Biotechnol 25 8 2007 911 920
17. F. Shojaei, J.H. Lee, and B.H. Simmons HGF/c-Met acts as an alternative angiogenic pathway in sunitinib-resistant tumors Cancer Res 70 24 2010 10090 10100 December 15, 2010
18. D. Huang, Y. Ding, and M. Zhou Interleukin-8 mediates resistance to antiangiogenic agent sunitinib in renal cell carcinoma Cancer Res 70 3 2010 1063 1071 Epub 2010 Jan 1026
19. C. Carbone, T. Moccia, and C. Zhu Anti-VEGF treatment-resistant pancreatic cancers secrete proinflammatory factors that contribute to malignant progression by inducing an EMT cell phenotype Clin Cancer Res 17 17 2011 5822 5832
20. M. Zhao, D. Sano, and C.R. Pickering Assembly and initial characterization of a panel of 85 genomically validated cell lines from diverse head and neck tumor sites Clin Cancer Res 17 23 2011 7248 7264 December 1, 2011
21. S. Kim, Y.D. Yazici, and G. Calzada Sorafenib inhibits the angiogenesis and growth of orthotopic anaplastic thyroid carcinoma xenografts in nude mice Mol Cancer Ther 6 6 2007 1785 1792
22. M.A. Ginos, G.P. Page, and B.S. Michalowicz Identification of a gene expression signature associated with recurrent disease in squamous cell carcinoma of the head and neck Cancer Res 64 1 2004 55 63 January 1, 2004
23. H. Ye, T. Yu, and S. Temam Transcriptomic dissection of tongue squamous cell carcinoma BMC Genomics 9 1 2008 69
24. A. Cromer, A. Carles, and R. Millon Identification of genes associated with tumorigenesis and metastatic potential of hypopharyngeal cancer by microarray analysis Oncogene 23 14 2004 2484 2498
25. J.Y. Yoo, J.H. Kim, and J. Kim Short hairpin RNA-expressing oncolytic adenovirus-mediated inhibition of IL-8: effects on antiangiogenesis and tumor growth inhibition Gene Ther 15 9 2008 635 651
26. E.P. Christofakis, H. Miyazaki, D.S. Rubink, and W.A. Yeudall Roles of CXCL8 in squamous cell carcinoma proliferation and migration Oral Oncol 44 10 Oct 2008 920 926
27. R. Salcedo, J.H. Resau, and D. Halverson Differential expression and responsiveness of chemokine receptors (CXCR1-3) by human microvascular endothelial cells and umbilical vein endothelial cells FASEB J: Official Publ Federation Am Soc Exp Biol 14 13 2000 2055 2064
28. A. Li, S. Dubey, M.L. Varney, B.J. Dave, and R.K. Singh IL-8 directly enhanced endothelial cell survival, proliferation, and matrix metalloproteinases production and regulated angiogenesis J Immunol 170 6 2003 3369 3376 March 15, 2003
29. S. Singh, K.C. Nannuru, A. Sadanandam, M.L. Varney, and R.K. Singh CXCR1 and CXCR2 enhances human melanoma tumourigenesis, growth and invasion Br J Cancer 100 10 2009 1638 1646
30. S. Singh, A. Sadanandam, and K.C. Nannuru Small-molecule antagonists for CXCR2 and CXCR1 inhibit human melanoma growth by decreasing tumor cell proliferation, survival, and angiogenesis Clin Cancer Res 15 7 2009 2380 2386
31. M.L. Petreaca, M. Yao, Y. Liu, K. Defea, and M. Martins-Green Transactivation of vascular endothelial growth factor receptor-2 by interleukin-8 (IL-8/CXCL8) is required for IL-8/CXCL8-induced endothelial permeability Molec Biol Cell 18 12 2007 5014 5023
32. J.R. Dunlevy, and J.R. Couchman Interleukin-8 induces motile behavior and loss of focal adhesions in primary fibroblasts J Cell Sci 108 Pt 1 Jan 1995 311 321
33. T. Cascone, M.H. Herynk, and L. Xu Upregulated stromal EGFR and vascular remodeling in mouse xenograft models of angiogenesis inhibitor-resistant human lung adenocarcinoma J Clin Invest 121 4 2011 1313 1328
34. F. Shojaei, X. Wu, and X. Qu G-CSF-initiated myeloid cell mobilization and angiogenesis mediate tumor refractoriness to anti-VEGF therapy in mouse models Proc Natl Acad Sci USA 106 16 2009 6742 6747
35. J. LeCouter, R. Lin, and M. Tejada The endocrine-gland-derived VEGF homologue Bv8 promotes angiogenesis in the testis: Localization of Bv8 receptors to endothelial cells Proc Natl Acad Sci USA 100 5 2003 2685 2690
36. J. LeCouter, C. Zlot, M. Tejada, F. Peale, and N. Ferrara Bv8 and endocrine gland-derived vascular endothelial growth factor stimulate hematopoiesis and hematopoietic cell mobilization Proc Natl Acad Sci USA 101 48 2004 16813 16818 November 30, 2004
37. S. Kopetz, P.M. Hoff, and J.S. Morris Phase II trial of infusional fluorouracil, irinotecan, and bevacizumab for metastatic colorectal cancer: efficacy and circulating angiogenic biomarkers associated with therapeutic resistance J Clin Oncol 28 3 2010 453 459 January 20, 2010
38. E.O. Hanrahan, H.Y. Lin, and E.S. Kim Distinct patterns of cytokine and angiogenic factor modulation and markers of benefit for vandetanib and/or chemotherapy in patients with non-small-cell lung cancer J Clin Oncol 28 2 2010 193 201
39. L. Yu, X. Wu, and Z. Cheng Interaction between bevacizumab and murine VEGF-A: a reassessment Invest Ophthalmol Visual Sci 49 2 2008 522 527
40. D. Vallbohmer, W. Zhang, and M. Gordon Molecular determinants of cetuximab efficacy J Clin Oncol: Official J Am Soc Clin Oncol 23 15 2005 3536 3544
41. R.W. Chapman, J.E. Phillips, R.W. Hipkin, A.K. Curran, D. Lundell, and J.S. Fine CXCR2 antagonists for the treatment of pulmonary disease Pharmacol Therap 121 1 Jan 2009 55 68
42. R. Bertini, L.S. Barcelos, and A.R. Beccari Receptor binding mode and pharmacological characterization of a potent and selective dual CXCR1/CXCR2 non-competitive allosteric inhibitor Brit J Pharmacol 165 2 Jan 2012 436 454